KR102093494B1 - TGFβ-유래 폴리펩티드 및 이들의 용도 - Google Patents

TGFβ-유래 폴리펩티드 및 이들의 용도 Download PDF

Info

Publication number
KR102093494B1
KR102093494B1 KR1020157011131A KR20157011131A KR102093494B1 KR 102093494 B1 KR102093494 B1 KR 102093494B1 KR 1020157011131 A KR1020157011131 A KR 1020157011131A KR 20157011131 A KR20157011131 A KR 20157011131A KR 102093494 B1 KR102093494 B1 KR 102093494B1
Authority
KR
South Korea
Prior art keywords
leu
cys
ser
pro
tyr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020157011131A
Other languages
English (en)
Korean (ko)
Other versions
KR20150083848A (ko
Inventor
앤젤 데 예수 코리아 오소리오
칼레트 레온 몬존
타니아 카르메나테 포르틸라
아마우리 푸포 메리노
사무엘 페레즈 로드리게스
Original Assignee
센트로 데 인뮤놀러지아 모레큘러
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49765213&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR102093494(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 센트로 데 인뮤놀러지아 모레큘러 filed Critical 센트로 데 인뮤놀러지아 모레큘러
Publication of KR20150083848A publication Critical patent/KR20150083848A/ko
Application granted granted Critical
Publication of KR102093494B1 publication Critical patent/KR102093494B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/495—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1841—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
KR1020157011131A 2012-11-09 2013-10-30 TGFβ-유래 폴리펩티드 및 이들의 용도 Active KR102093494B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CU20120158A CU24181B1 (es) 2012-11-09 2012-11-09 POLIPÉPTIDOS DERIVADOS DEL TGFß
CUCU/P/2012/0158 2012-11-09
PCT/CU2013/000007 WO2014071894A1 (es) 2012-11-09 2013-10-30 POLIPÉPTIDOS DERIVADOS DEL TGFβ Y SUS USOS

Publications (2)

Publication Number Publication Date
KR20150083848A KR20150083848A (ko) 2015-07-20
KR102093494B1 true KR102093494B1 (ko) 2020-03-26

Family

ID=49765213

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020157011131A Active KR102093494B1 (ko) 2012-11-09 2013-10-30 TGFβ-유래 폴리펩티드 및 이들의 용도

Country Status (27)

Country Link
US (1) US9701730B2 (enExample)
EP (1) EP2918284B1 (enExample)
JP (2) JP6298823B2 (enExample)
KR (1) KR102093494B1 (enExample)
CN (1) CN104902916B (enExample)
AR (1) AR093391A1 (enExample)
AU (1) AU2013344022B2 (enExample)
BR (1) BR112015010145B1 (enExample)
CA (1) CA2887455C (enExample)
CL (1) CL2015001252A1 (enExample)
CO (1) CO7400865A2 (enExample)
CU (1) CU24181B1 (enExample)
EA (1) EA031990B1 (enExample)
ES (1) ES2857176T3 (enExample)
IL (1) IL238621B (enExample)
JO (1) JO3502B1 (enExample)
MX (1) MX366060B (enExample)
MY (1) MY173078A (enExample)
NZ (1) NZ707850A (enExample)
PE (1) PE20150890A1 (enExample)
PH (1) PH12015500807A1 (enExample)
SG (1) SG11201502980VA (enExample)
TN (1) TN2015000129A1 (enExample)
TW (1) TWI615404B (enExample)
UA (1) UA115678C2 (enExample)
WO (1) WO2014071894A1 (enExample)
ZA (1) ZA201504462B (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018094173A1 (en) * 2016-11-18 2018-05-24 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Engineered tgf-beta monomers and their use for inhibiting tgf-beta signaling
PL238850B1 (pl) * 2017-10-19 2021-10-11 Calther Polska Spolka Z Ograniczona Odpowiedzialnoscia Aktywna forma transformującego czynnika wzrostu beta 1 (TGFβ1) do zastosowania w leczeniu pacjentów z glejakami wielopostaciowymi, w przypadku których to glejaków ponad 5% komórek nowotworowych jest EGFRvIII-pozytywna
CN119285746A (zh) * 2024-10-24 2025-01-10 湖南中晟全肽生物科技股份有限公司 作为TGF-β受体激动剂肽的化合物及其用途

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1328569A (zh) 1998-11-24 2001-12-26 纳瓦拉公司科学与技术研究所 TGFβ1－抑制肽
US20020169292A1 (en) 1998-09-22 2002-11-14 Weintraub Bruce D. Cystine knot growth factor mutants

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1087998A1 (en) * 1998-06-16 2001-04-04 Biogen, Inc. Variant type ii tgf-beta receptor fusion proteins and methods
US6677432B1 (en) * 1998-10-07 2004-01-13 Stryker Corporation Mutations of the C-terminal portion of TGF-β superfamily proteins
CA2575278A1 (en) * 2004-06-30 2006-01-19 Molecular Logix, Inc. Epidermal growth factor receptor antagonists and methods of use
US7795389B2 (en) * 2004-09-28 2010-09-14 The Board Of Regents Of The University Of Texas System Antagonizing TGF-beta activity with various ectodomains TGF-beta receptors used in combination or as fusion proteins
CN101365712A (zh) * 2005-01-11 2009-02-11 莫勒丘尔洛吉克斯有限公司 Pan-HER拮抗剂及其使用方法
GB0724051D0 (en) * 2007-12-08 2008-01-16 Medical Res Council Mutant proteins and methods for producing them
CA2796706A1 (en) * 2010-04-22 2011-10-27 The Medical Research, Infrastructure, And Health Services Fund Of The Te L Aviv Medical Center High affinity leptins and leptin antagonists

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020169292A1 (en) 1998-09-22 2002-11-14 Weintraub Bruce D. Cystine knot growth factor mutants
CN1328569A (zh) 1998-11-24 2001-12-26 纳瓦拉公司科学与技术研究所 TGFβ1－抑制肽
US20070014767A1 (en) * 1998-11-24 2007-01-18 Ezquerro Saenz Ignacio J TGFbeta1-inhibitor peptides

Also Published As

Publication number Publication date
PE20150890A1 (es) 2015-06-10
EA201590914A1 (ru) 2015-09-30
AU2013344022B2 (en) 2016-12-15
KR20150083848A (ko) 2015-07-20
TWI615404B (zh) 2018-02-21
CN104902916B (zh) 2018-04-13
JP6298823B2 (ja) 2018-03-20
ZA201504462B (en) 2018-11-28
CA2887455C (en) 2022-05-17
PH12015500807A1 (en) 2015-06-08
UA115678C2 (uk) 2017-12-11
HK1213781A1 (zh) 2016-07-15
MX2015005875A (es) 2015-09-10
US9701730B2 (en) 2017-07-11
JO3502B1 (ar) 2020-07-05
NZ707850A (en) 2019-08-30
US20150284441A1 (en) 2015-10-08
AU2013344022A1 (en) 2015-05-28
ES2857176T3 (es) 2021-09-28
CL2015001252A1 (es) 2015-07-17
SG11201502980VA (en) 2015-06-29
EA031990B1 (ru) 2019-03-29
CN104902916A (zh) 2015-09-09
EP2918284A1 (en) 2015-09-16
JP2018111703A (ja) 2018-07-19
CU20120158A7 (es) 2014-06-27
TN2015000129A1 (en) 2016-10-03
TW201431875A (zh) 2014-08-16
MY173078A (en) 2019-12-25
CU24181B1 (es) 2016-04-25
JP6608473B2 (ja) 2019-11-20
JP2015535000A (ja) 2015-12-07
IL238621B (en) 2019-12-31
CO7400865A2 (es) 2015-09-30
CA2887455A1 (en) 2014-05-15
MX366060B (es) 2019-06-26
EP2918284B1 (en) 2021-02-17
WO2014071894A1 (es) 2014-05-15
AR093391A1 (es) 2015-06-03
BR112015010145A2 (enExample) 2017-08-22
IL238621A0 (en) 2015-06-30
BR112015010145B1 (pt) 2022-06-07

Similar Documents

Publication Publication Date Title
JP7767290B2 (ja) 新規なマスクされたサイトカインおよびその使用方法
RU2517596C2 (ru) МОНОКЛОНАЛЬНЫЕ АНТИТЕЛА, КОТОРЫЕ СВЯЗЫВАЮТСЯ С hGM-CSF, И СОДЕРЖАЩИЕ ИХ КОМПОЗИЦИИ МЕДИЦИНСКОГО НАЗНАЧЕНИЯ
Gadó et al. Role of interleukin‐6 in the pathogenesis of multiple myeloma
CN103201284B (zh) 用于癌症和慢性感染的治疗的具有激动剂活性的衍生自il-2的多肽
US7947265B2 (en) Fusion proteins and methods for modulation of immune response
RU2711979C2 (ru) Белковый комплекс интерлейкина 15 и его применение
US20120315245A1 (en) Immunomodulator polypeptides derived from il-2 and their use thereof in the therapeutic of cancer and chronic infections
ES2774422T3 (es) Anticuerpos para IL-21
CN110461871A (zh) 白蛋白结合结构域融合蛋白
JP6608473B2 (ja) ＴＧＦβに由来するポリペプチド及びその使用
Kusters et al. Cytokines and immune responses in murine atherosclerosis
KR20230117341A (ko) 다기능성 및 다가 인터류킨-tgf-베타 수용체 융합 폴리펩티드
ZA200703528B (en) Immunotherapeutic formulations with Interleukin-2-neutralising capacity
TW201834693A (zh) 增強免疫反應之組合物及方法
HK1213781B (en) POLYPEPTIDES DERIVED FROM TGFβ AND USES THEREOF
CN118974093A (zh) 包含抗cd73抗体和il-2的融合蛋白及其用途
JP2025538207A (ja) 操作されたインターロイキン－１５ポリペプチド、その複合体、およびその使用
HK1182403B (en) Polypeptides derived from il-2 having agonist activity, for the therapy of cancer and chronic infections

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20150428

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20180731

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20190807

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20200226

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20200319

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20200320

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
PR1001 Payment of annual fee

Payment date: 20221212

Start annual number: 4

End annual number: 4

PR1001 Payment of annual fee

Payment date: 20231214

Start annual number: 5

End annual number: 5